Pfizer To Buy Cancer Biotech Company Trillium For $2.3 Million
For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It's completely free and we guarantee you'll learn something new every day.
What do you do when you're brimming with billions of dollars in new vaccine revenue? You splurge, of course!
That's the mindset Pfizer is taking, flush with a projected $33.5 billion in vaccine revenue this year. The first purchase of the pharmaceutical giant's shopping spree: cancer biotech company Trillium, which Pfizer announced on Monday it agreed to acquire for a hefty sum.
Source Fool.com
